Bellevue Asset Management, manager of the BB Biotech trust, is to expand its range with the launch of a broader healthcare investment trust today.
Zurich-based Bellevue has $4bn invested in the healthcare industry and is seeking to raise £200m for the new trust. It will be a high conviction, long-only investment trust invested in listed or quoted global healthcare equities and have a maximum of 35 holdings. The trust will be able to invest regardless of market cap, sector or region and will have a broader remit than the specialist BB Biotech trust. Holdings could include pharmaceuticals, biotechnology, medical devices, healthcare insurers and drug retail with the firm saying it expects the majority of exposure will come from th...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
